Andrew Oshaughnessy, MD
Nephrology · Fort Wayne, INNPI 1568416865
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $56,218 of the $63,597 with a category attached, or 88.4%. 26 manufacturers reported payments, led by Boehringer Ingelheim at 55.8% of the total. Among nephrology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $202.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$35K
- Lilly USA, LLC$23K
- Bayer$1K
- Otsuka America Pharmaceutical, Inc.$548
- Amgen$513
- Vifor Pharma, Inc.$491
- plus $2K from 20 others
Across 639 payments — averaging $1855.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$786K
- GSK$238K
- Eli Lilly$70K
- CSL Behring$38K
- AstraZeneca$26K
- E.r. Squibb & Sons, L.L.C.$11K
- plus $16K from 5 others
What the payments were for
- Speaking & faculty fees$56,21888%
- Travel & lodging$1,3672%
- Food & beverage$5,7909%
- Education$2230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 45 | $35,498 |
| Lilly USA, LLC | 38 | $22,948 |
| Bayer | 62 | $1,118 |
| Otsuka America Pharmaceutical, Inc. | 17 | $548 |
| Amgen(2 entities) | 24 | $513 |
| Vifor Pharma, Inc. | 15 | $491 |
| AstraZeneca(2 entities) | 21 | $434 |
| Akebia Therapeutics Inc | 23 | $370 |
| Fresenius USA Marketing, Inc. | 16 | $334 |
| Mallinckrodt Hospital Products Inc. | 7 | $249 |
| Novartis | 8 | $139 |
| Travere Therapeutics, Inc. | 5 | $129 |
| Alnylam Pharmaceuticals Inc. | 1 | $121 |
| Calliditas Therapeutics US Inc. | 5 | $101 |
| Bard Peripheral Vascular, Inc. | 1 | $101 |
| GSK | 5 | $74 |
| Nxstage Medical, Inc. | 1 | $71 |
| Ardelyx, Inc. | 4 | $69 |
| OPKO Pharmaceuticals, LLC | 4 | $66 |
| Aurinia Pharma U.S., Inc. | 3 | $59 |
| Daiichi Sankyo Inc. | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Novo Nordisk | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$63,597 in reported general payments places this provider in the 95th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 84 | $67,077 |
| FarxigaDapagliflozin Propanediol | 50 | $36,503 |
| KerendiaFinerenone | 18 | $30,725 |
| MounjaroTirzepatide | 22 | $23,751 |
| AuryxiaFerric Citrate | 14 | $18,081 |
| Lanthanum Carbonate | 19 | $16,897 |
| Sevelamer Carbonate | 50 | $9,182 |
| Potassium Chloride | 43 | $2,039 |
| Minoxidil | 19 | $1,096 |
| Temazepam | 20 | $904 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 17 | $806 |
| Midodrine Hcl | 11 | $563 |
| Torsemide | 16 | $501 |
| Calcium Acetate | 12 | $463 |
| Gentamicin Sulfate | 48 | $433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $35,498 | $67,07784 claims |
| AstraZenecaFarxiga | $434 | $36,50350 claims |
| BayerKerendia | $1,118 | $30,72518 claims |
| Lilly USA, LLCMounjaro | $22,948 | $23,75122 claims |
| Akebia Therapeutics IncAuryxia | $370 | $18,08114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 238 nephrology providers in Indiana.
Other nephrology in Fort Wayne
- John DuckerFort Wayne$8K
- Melanie BarridoFort Wayne$6K
- Irfan MunirFort Wayne$5K
- Sajjad HabibFort Wayne$4K
- Kanakapura VenkatakrishnaFort Wayne$4K
- Kiran Mandya ChikkalingaiahFort Wayne$4K
- Prasanna IsaacFort Wayne$3K
- Garima GuptaFort Wayne$3K
- Guy AsherFort Wayne$3K
- Rajiv AgarwalIndianapolis$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.